Also, Guo and colleagues reported that the RAF–MEK inhibitor RO-5126766 had antitumor activity against several solid tumors and MM with RAF–RAS–MEK pathway mutations [113]. This evidence concerns the gene MAP2K7 and Miyoshi myopathy.